TPX2 and pancreatic ductal adenocarcinoma: Additionally, in pancreatic ductal adenocarcinoma (PDAC), high TPX2 levels are associated with diminished efficacy of gemcitabine-based chemotherapy, indicating its potential as a predictive marker for gemcitabine resistance [48].